So How Does SERCA Work?

001). The duration per episode of nausea or vomiting in the dronabinol group was 2 and 10 minutes versus 4 and 15 minutes in the prochlorperazine group. However, the total duration of nausea and vomiting episodes did not differ between the three treatment groups. Eleven patients reported anticipatory nausea (30% in dronabinol group, 0% in the prochlorperazine group, and 26% in the combination group). Thirty-four patients reported adverse drug effects in the dronabinol (n=16), prochlorperazine (n=7), and combination Selleck Volasertib (n=11) groups.12 The difference of reported adverse drug effects was statistically significant between the dronabinol and prochlorperazine groups (Pclick here be increased or decreased as tolerated. Another option for dosing dronabinol is 5 mg/m2 PO every 1�C3 hours prechemotherapy and then every 2�C4 hours for a total of 4�C6 doses/d. The maximum individual dose is 15 mg/m2. Patient perspectives of dronabinol CB1/CB2 receptor agonists can produce adverse effects in patients, and many of these are likely caused by the activation of central CB1 receptors rather than CB2 or peripheral CB1 receptors.5 In 18 cross-over trials included in the Tramer et al10 metaanalysis, SERCA when patients were questioned which antiemetic was preferred, 38%�C90% of patients preferred cannabinoids. Four trials compared cannabinoids to placebo. Out of 202 patients, 153 patients preferred cannabinoids versus 27 patients preferring the placebo (NNT =1.6). In ten additional trials comparing cannabinoids to an active control, 371 out of 604 (61%) preferred cannabinoids versus 156 patients (26%) preferring the active control. In the Rocha et al��s11 meta-analysis, 18 double-blind and cross-over trials (n=1,138) included an analysis of the patient��s preference of cannabinoids, and it resulted in a statistically significant difference in favor of cannabinoids (NNT =1.8, P